Diabetic Ketoacidosis
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Colorado TherapeuticsGlargine
DexcomDEXCOM G6 CGM
Novo NordiskInsulin
Clinical Trials (3)
Total enrollment: 274 patients across 3 trials
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
Start: Jul 2017Est. completion: Mar 202161 patients
Phase 4Completed
Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)
Start: Jun 2022Est. completion: Mar 2023163 patients
N/ACompleted
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Start: Jan 2005Est. completion: Dec 200750 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.